[HTML][HTML] Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN …
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical …
HL Kaufman, JS Russell, O Hamid, S Bhatia… - … for immunotherapy of …, 2018 - Springer
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial …
poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial …
[HTML][HTML] First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II …
Background Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple
countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and …
countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and …
[HTML][HTML] Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
JW Walker, C Lebbé, G Grignani, P Nathan… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Avelumab, a human anti–programmed death-ligand 1 immunoglobulin G1
monoclonal antibody, showed favorable efficacy and safety in patients with metastatic …
monoclonal antibody, showed favorable efficacy and safety in patients with metastatic …
Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial
SP D'Angelo, J Russell, C Lebbé, B Chmielowski… - JAMA …, 2018 - jamanetwork.com
Importance Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated
with poor survival outcomes in patients with distant metastatic disease. Results of part A of …
with poor survival outcomes in patients with distant metastatic disease. Results of part A of …
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
HL Kaufman, J Russell, O Hamid, S Bhatia… - The lancet …, 2016 - thelancet.com
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
V Glutsch, H Kneitz, A Gesierich, M Goebeler… - Cancer Immunology …, 2021 - Springer
Background Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine
cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are …
cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are …
[HTML][HTML] Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor
survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
Merkel cell carcinoma in the age of immunotherapy: facts and hopes
Merkel cell carcinoma (MCC) is a rare (∼ 2,000 US cases/year) but aggressive
neuroendocrine tumor of the skin. For advanced MCC, cytotoxic chemotherapy only …
neuroendocrine tumor of the skin. For advanced MCC, cytotoxic chemotherapy only …
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a …
Background Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer.
Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 …
Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 …